369 related articles for article (PubMed ID: 20863155)
41. [Genotyping and minimal residual disease study in children with acute myeloid leukemia: preliminary results].
Balwierz W; Pietrzyk JJ; Wator G; Stozek K; Klekawka T; Kwiecińska K; Dłuzniewska A; Matysiak M; Malinowska I; Sikorska-Fic B; Balcerska A; Maciejka-Kapuścińska L; Sońta-Jakimczyk D; Tomaszewska R; Chybicka A; Krawczuk-Rybak M; Muszyńska-Rosłan K; Młynarski W; Stolarska M; Urasiński T; Kamieńska E; Sobol G; Wieczorek M; Karolczyk G; Wysocki M; Kołtan S; Kowalczyk JR; Wójcik B; Ksiazek T; Szewczyk K
Przegl Lek; 2010; 67(6):371-4. PubMed ID: 21344764
[TBL] [Abstract][Full Text] [Related]
42. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis.
Galimberti S; Guerrini F; Carulli G; Fazzi R; Palumbo GA; Morabito F; Petrini M
Eur J Haematol; 2004 Jan; 72(1):45-51. PubMed ID: 14962262
[TBL] [Abstract][Full Text] [Related]
43. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
[TBL] [Abstract][Full Text] [Related]
44. [Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile].
Artigas CG; Melo A; Roa JC; Páez E; Vittini C; Arriagada M; González L; Pflaumer E; Roa I
Rev Med Chil; 2002 Jun; 130(6):623-30. PubMed ID: 12194684
[TBL] [Abstract][Full Text] [Related]
45. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry.
Trka J; Kalinová M; Hrusák O; Zuna J; Krejcí O; Madzo J; Sedlácek P; Vávra V; Michalová K; Jarosová M; Starý J;
Leukemia; 2002 Jul; 16(7):1381-9. PubMed ID: 12094264
[TBL] [Abstract][Full Text] [Related]
46. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
[TBL] [Abstract][Full Text] [Related]
47. High expression of WT1 gene in acute myeloid leukemias with more predominant WT1+17AA isoforms at relapse.
Gu W; Hu S; Chen Z; Qiu G; Cen J; He B; He J; Wu W
Leuk Res; 2010 Jan; 34(1):46-9. PubMed ID: 19414192
[TBL] [Abstract][Full Text] [Related]
48. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
49. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
50. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
Willasch AM; Gruhn B; Coliva T; Kalinova M; Schneider G; Kreyenberg H; Steinbach D; Weber G; Hollink IH; Zwaan CM; Biondi A; van der Velden VH; Reinhardt D; Cazzaniga G; Bader P; Trka J;
Leukemia; 2009 Aug; 23(8):1472-9. PubMed ID: 19322206
[TBL] [Abstract][Full Text] [Related]
51. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
[TBL] [Abstract][Full Text] [Related]
52. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
[TBL] [Abstract][Full Text] [Related]
53. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia.
Andersson C; Li X; Lorenz F; Golovleva I; Wahlin A; Li A
Diagn Mol Pathol; 2012 Dec; 21(4):225-33. PubMed ID: 23111196
[TBL] [Abstract][Full Text] [Related]
54. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
[TBL] [Abstract][Full Text] [Related]
55. [Individualized treatment of leukemia patients by monitoring of minimal residual disease (MRD) based on WT1 assay].
Ogawa H; Sugiyama H
Rinsho Ketsueki; 1998 Feb; 39(2):107-8. PubMed ID: 9545812
[No Abstract] [Full Text] [Related]
56. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
[TBL] [Abstract][Full Text] [Related]
57. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
[No Abstract] [Full Text] [Related]
58. Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias.
Kreuzer KA; Saborowski A; Lupberger J; Appelt C; Na IK; le Coutre P; Schmidt CA
Br J Haematol; 2001 Aug; 114(2):313-8. PubMed ID: 11529849
[TBL] [Abstract][Full Text] [Related]
59. [Studies of hTERT gene expression in acute leukemia children].
Li X; Wang X; Li X; Liu B; Zhang Y; Liao Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):486-8. PubMed ID: 12910697
[TBL] [Abstract][Full Text] [Related]
60. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
